HomeCompareRXDX vs PG

RXDX vs PG: Dividend Comparison 2026

RXDX yields 1.00% · PG yields 2.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PG wins by $30.3K in total portfolio value
10 years
RXDX
RXDX
● Live price
1.00%
Share price
$199.92
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.1K
Annual income
$106.75
Full RXDX calculator →
PG
Procter & Gamble
● Live price
2.92%
Share price
$144.73
Annual div
$4.23
5Y div CAGR
31.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.4K
Annual income
$9,955.44
Full PG calculator →

Portfolio growth — RXDX vs PG

📍 PG pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRXDXPG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RXDX + PG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RXDX pays
PG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RXDX
Annual income on $10K today (after 15% tax)
$85.03/yr
After 10yr DRIP, annual income (after tax)
$90.74/yr
PG
Annual income on $10K today (after 15% tax)
$248.27/yr
After 10yr DRIP, annual income (after tax)
$8,462.12/yr
At 15% tax rate, PG beats the other by $8,371.39/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RXDX + PG for your $10,000?

RXDX: 50%PG: 50%
100% PG50/50100% RXDX
Portfolio after 10yr
$36.3K
Annual income
$5,031.10/yr
Blended yield
13.87%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PG right now

RXDX
Analyst Ratings
4
Buy
7
Hold
Consensus: Hold
Price Target
$138.57
-30.7% upside vs current
Range: $67.00 — $200.00
Altman Z
94.1
Piotroski
2/9
PG
Analyst Ratings
29
Buy
22
Hold
1
Sell
Consensus: Buy
Price Target
$167.67
+15.9% upside vs current
Range: $150.00 — $179.00
Altman Z
5.3
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RXDX buys
0
PG buys
0
No recent congressional trades found for RXDX or PG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRXDXPG
Forward yield1.00%2.92%
Annual dividend / share$2.00$4.23
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%31.1%
Portfolio after 10y$21.1K$51.4K
Annual income after 10y$106.75$9,955.44
Total dividends collected$1.0K$29.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldBuy
Analyst price target$138.57$167.67

Year-by-year: RXDX vs PG ($10,000, DRIP)

YearRXDX PortfolioRXDX Income/yrPG PortfolioPG Income/yrGap
1← crossover$10,800$100.04$11,003$382.92$203.00PG
2$11,657$100.98$12,205$520.11$548.00PG
3$12,575$101.86$13,674$712.22$1.1KPG
4$13,558$102.69$15,507$985.02$1.9KPG
5$14,610$103.47$17,847$1,378.96$3.2KPG
6$15,737$104.21$20,913$1,959.19$5.2KPG
7$16,944$104.91$25,044$2,834.00$8.1KPG
8$18,235$105.56$30,786$4,189.46$12.6KPG
9$19,618$106.17$39,052$6,357.54$19.4KPG
10$21,098$106.75$51,429$9,955.44$30.3KPG

RXDX vs PG: Complete Analysis 2026

RXDXStock

Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR600, an anti-tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; PR1800, an anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California.

Full RXDX Calculator →

PGConsumer Staples

The Procter & Gamble Company provides branded consumer packaged goods worldwide. It operates through five segments: Beauty; Grooming; Health Care; Fabric & Home Care; and Baby, Feminine & Family Care. The Beauty segment offers conditioners, shampoos, styling aids, and treatments under the Head & Shoulders, Herbal Essences, Pantene, and Rejoice brands; and antiperspirants and deodorants, personal cleansing, and skin care products under the Olay, Old Spice, Safeguard, Secret, and SK-II brands. The Grooming segment provides shave care products and appliances under the Braun, Gillette, and Venus brand names. The Health Care segment offers toothbrushes, toothpastes, and other oral care products under the Crest and Oral-B brand names; and gastrointestinal, rapid diagnostics, respiratory, vitamins/minerals/supplements, pain relief, and other personal health care products under the Metamucil, Neurobion, Pepto-Bismol, and Vicks brands. The Fabric & Home Care segment provides fabric enhancers, laundry additives, and laundry detergents under the Ariel, Downy, Gain, and Tide brands; and air care, dish care, P&G professional, and surface care products under the Cascade, Dawn, Fairy, Febreze, Mr. Clean, and Swiffer brands. The Baby, Feminine & Family Care segment offers baby wipes, taped diapers, and pants under the Luvs and Pampers brands; adult incontinence and feminine care products under the Always, Always Discreet, and Tampax brands; and paper towels, tissues, and toilet papers under the Bounty, Charmin, and Puffs brands. The company sells its products primarily through mass merchandisers, e-commerce, grocery stores, membership club stores, drug stores, department stores, distributors, wholesalers, specialty beauty stores, high-frequency stores, pharmacies, electronics stores, and professional channels, as well as directly to consumers. The Procter & Gamble Company was founded in 1837 and is headquartered in Cincinnati, Ohio.

Full PG Calculator →
📬

Get this RXDX vs PG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RXDX vs SCHDRXDX vs JEPIRXDX vs ORXDX vs KORXDX vs MAINRXDX vs KMBRXDX vs CLRXDX vs CHD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.